Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. financial statements

Foghorn Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

FY2025

RevenueUSD 30.91M10-K
Net income−USD 74.28M10-K
Cash and equivalentsUSD 80.88M10-Q
Total debtUSD 41.27MEODHD

Foghorn Therapeutics Inc. financials on 6ix · Foghorn Therapeutics Inc. on 6ix